Barrier Clause Samples

Barrier. The barrier shall consist of a block of reinforced concrete not less than 3 m wide in front and not less than 1.5 m high. The barrier shall be of such thickness that it weighs at least 70 metric tons. The front face shall be flat, vertical and perpendicular to the axis of the run-up track. It shall be covered with plywood boards 20 ± 2 mm thick, in good condition. A structure on a steel plate at least 25 mm thick may be placed between the plywood board and the barrier. A barrier with different characteristics may likewise be used, provided that the area of the impact surface is greater than the frontal crash area of the vehicle being tested and provided that it gives equivalent results.

Barrier. The front face of the barrier consists of a deformable structure as defined in Annex 9 of this Regulation. The front face of the deformable structure is perpendicular within ± 1° to the direction of travel of the test vehicle. The barrier is secured to a mass of not less than 7 x 104 kg, the front face of which is vertical within ± 1°. The mass is anchored in the ground or placed on the ground with, if necessary, additional arresting devices to restrict its movement.

Barrier. Revise to read as follows: (a)Barrier.

Barrier. Any surface that seals off the work area to inhibit the movement of fibers.

Barrier. The barrier … The barrier shall be of such … The front face shall be vertical … be used."

Barrier. Equipment preventing entry by an unauthorized person to a restricted area, structure or building, and providing physical protection against direct contact with Energized Parts under normal circumstances.

Barrier. 2.1.1 Barrier will provide Abbott with [**] kg of Triaset mixture, free of charge, together with any information on drug handling, safety and relevant toxicolgical data for Drug Substance (at least MDMS) which Abbott has not previously received. 2.1.2 Barrier will provide and/or update Abbott with full details of the draft assay, related substances and disssolution methods which Abbott has not previously received. 2.1.3 Barrier will provide Abbott with samples of the Drug Substance extrudate produced on the Janssen [**]

Barrier. 2.1.1 Barrier has provided Abbott with material under the SCHEDULES B-1 and B-2 and Abbott will now use up the remainder. 2.1.2 Barrier will perform milling and tabletting of the Bulk Product for technical assessment.

Barrier. 2.1.1 Barrier will provide Abbott with [**] kg of GMP-quality Drug Substance (as Itraconazole) and [**] kg of GMP-quality HPMC free of charge together with a Certificate of Analysis and any information on drug handling, safety and relevant ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. toxicolgical data for Drug Substance (at least MSDS) which Abbott has not previously received. 2.1.2 Barrier will perform the analytical testing necessary to release the Bulk Product for further processing. 2.1.3 Barrier will perform milling and tabletting of the Bulk Product to manufacture the Finished Product applicable for clinical trial supply. 2.1.4 Barrier will perform the final release of the clinical trial samples.